This past week the Wall Street Journal printed an article following the announcement by Health Secretary Kennedy that the FDA was going to lift restrictions on peptide treatments. We are noting a rising of patient self-reporting consumption of peptide therapy protocols. Many of these patients are doing this in addition to paying us for comprehensive medical access and care. At this point, I felt it is time for my own self education and to post to the public on this topic.

Interestingly, despite Americans shouting that health care is unaffordable, it appears a big chunk of people are willing to shell out big bucks to keep up with the Jones’. Keep this in mind the next time your neighbor or a stranger tells you they can’t afford health care.

When you combine peptides and hormone therapy, you’re no longer looking at fringe medicine—you’re looking at a multi-billion-dollar, cash-pay health economy operating in plain sight, largely outside the traditional health care access point, namely doctors.

And if we add the gateway to Peptide therapy, namely, alternative hormone replacement therapy we see an even larger spend going on…

Globally this market may be 30 billion dollars or more.

It makes sense to me that Secretary Kennedy would loosen restrictions on peptides. He gets to poke big pharma in the eye for starters. The COVID 19 pandemic provided the opportunity for loosened compound pharmacy regulation. Big pharma couldn’t meet market demand for Ozempic and Mounjaro. Shortages are a scenario where patent law can be suspended and President Biden's administration did just that. The result was a rapid response “black/gray market for the generic/compounded versions of Ozempic and Mounjaro. These patent protected prescriptions aren’t typical pharma chemical molecules. They are, in fact… peptides called Glp-1 agonists. Actually these compounds make up the Lion’s share of the current US and likely global peptide market.

Noting the success of these scientifically studied and proven human peptide analogues (Glp1 agonists), I am learning that the telehealth supply chain and the non-physician hormone and aesthetic store fronts are pitching unproven but theoretically plausible peptide stacks onto patients. All of them promise leaner body fat and improved muscle and ligament healing. A more powerful and youthful YOU so to speak. Objectively the results can all be explained by the Glp-agonists but hey, why not jab yourself with some more products and get even “better” outcomes.

As a physician, I am chagrined as well as concerned about health extenders opening infusion clinics, pumping vitamins, amino acids, and who knows for sure what all into hangover victims and folks that just want to feel better.

According to Contrary Research:

The GLP-1 compounding boom demonstrated that patients are increasingly use alternative, consumerized care pathways when conventional channels are slow or expensive. Telehealth, cash pay, and compounding pharmacies functioned as a scalable distribution system for GLP-1s, filling a supply and access gap for a blockbuster therapy. These channels did more than fill a temporary gap: they demonstrated that patients will route around insurer-mediated pathways when access is slow, coverage is uncertain, or prices are high. In doing so, these pathways expanded drug access and customization, but often with less oversight and frequent conflicts with patent protections.

The growth of compounding also highlighted a longstanding tension in biopharma: patent exclusivity is designed to reward costly R&D, yet high prices and uneven coverage can create strong pressure for workarounds. Compounded GLP-1s exposed how quickly those workarounds can now scale. This pattern will likely be reproduced with future high-demand therapies, forcing regulators, manufacturers, and clinicians to balance access, safety, and incentives for innovation as more care moves outside traditional clinical settings and insurer-mediated systems.

Peptides- What Do We Know About This Therapeutic Class?

Peptides (Non-Biologics): Any polymer composed of 40 or fewer amino acids is generally classified as a drug (small molecule). These fall under the Hatch-Waxman Act for patenting and generic approvals. The first patented therapeutic peptide is insulin.

Historical Context

• Defining the Class: Insulin was the first substance to prove that a peptide (a chain of amino acids) could serve as a life-saving drug. It is a 51-amino acid peptide, though modern regulatory definitions (like the Hatch-Waxman Act mentioned in your draft) sometimes distinguish between “small” peptides (under 40 amino acids) and larger proteins. The law changed in 2020 regarding peptide definition. This is why insulin is still considered the first peptide despite having 51 amino acids. So, legally speaking, the FDA now classifies insulin as a protein/biologic, not a peptide. This transition was designed to open the door for biosimilars (the biologic version of generics).

• First Synthetic Versions: Decades later, insulin continued its “firsts” by becoming the first recombinant DNA (biotechnological) drug approved by the FDA in 1982 (Humulin).

There are many peptides that are prescription medications. Examples include the Glp-1 agonist peptides. Namely, liraglutide, semaglutide, tirzepatide. Liraglutide is a daily injection now available generically. The other two are the name brand products we all know and love which are also currently still being offered in compounding pharmacies. Other examples include teriparatide (Forteo) used for osteoporosis treatment, desmopressin (DDAVP) used for diabetes insipidus and bedwetting, and bremelanotide (Vyleesi) for female sexual dysfunction.

As of late March 2026, the specific number of peptides moving to Category 1 is 14, according to the directive from Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. Category one allows legal marketing and preparation and are considered posing no significant safety risks.

On February 27, 2026, Secretary Kennedy announced a major policy shift to “end the war on peptides” by reclassifying approximately 14 of the 19 peptides that the FDA had previously restricted in late 2023. ¹

Following the landmark February 2026 announcement regarding the reclassification of therapeutic compounds, several “trendy” peptides are making a high-profile return to compounding pharmacies. These options have become particularly popular in anti-aging and recovery protocols:

• BPC-157 (Healing & Recovery): Often called the “Body Protection Compound,” this peptide is a favorite for systemic repair, specifically targeting gut health and the accelerated healing of tendons and ligaments.

• GHK-Cu (Skin & Anti-Aging): A naturally occurring copper peptide frequently used in both premium serums and injections to stimulate collagen production and visibly reduce wrinkles.

• AOD-9604 (Targeted Fat Loss): This fragment of Human Growth Hormone is designed to trigger lipolysis (fat burning) without the unwanted side effect of affecting blood sugar levels.

• MOTS-c (Metabolic Health): Widely referred to as an “exercise mimetic,” it is prized for its ability to boost mitochondrial function and overall cellular energy.

• CJC-1295 / Ipamorelin (Growth Hormone Support): Typically administered as a synergistic “stack,” these peptides stimulate the body’s natural growth hormone production to improve deep sleep and support muscle maintenance.

Patients are coming in telling me they are getting the Wolverine stack. I am thinking “what???”.

The “Wolverine Stack” (or Wolverine Blend) is a popular nickname for the combination of two specific regenerative peptides: BPC-157 and TB-500 (Thymosin Beta-4). It is named after the Marvel character because of the intended effect of “superhuman” healing and tissue repair.

Enter the Rub

While there are many scientific articles discussing the mechanisms of these peptides, there is currently no large-scale, double-blind, placebo-controlled human trial that validates the specific “Wolverine Stack” (BPC-157 + TB-500) for injury recovery or anti-aging. This is true for most of these products. What this means to me as a physician is, most of these programs have inadequate scientific backing and as such the claims can be wildly far off from any actual therapeutic result. Further, since these products are often given concomitantly with hormones, vitamins, and exercise programs, it is essentially impossible to know what of these variables is having real effects or not.

What’s the Harm Doc?

Even exercise recommendations have potential for harm. I don’t think harm is any less expected or anticipated from artificially injecting our body with potentially bioactive peptides. Further, if we provide our bodies with essentially replacement peptides for naturally synthesized active peptides, it seems predictable that we will alter normal peptide regulation and genetic signalling. Many of these molecules communicate with other naturally communicating networks and hormone pathways. In a true deficiency a therapeutic result may certainly occur. In the absence of a true deficiency, these injections may create true biologic metabolic confusion. Which tests are the proper tests to measure for peptide deficiency? How do we objectively measure for outcomes? What safety signals should we be monitoring for and how can we determine such concerns are real or linked to therapy?

Call me old fashioned but I think you want physicians helping you monitor these rather loosely dispensed treatment protocols. As I have stated in a prior post- be careful what you read. Also buyer beware.

Some Other Interesting Peptide Tidbits

The quest for oral peptide delivery is often called the “Holy Grail” of pharmacology. While traditional drugs are small, robust molecules, peptides are large, fragile chains of amino acids that the human body is expertly designed to destroy as “food” (protein).

Here are the specific limitations and the cutting-edge technological developments as of 2026.

1. Key Limitations (The Biological Gauntlet)

• The “Acid Bath”: The stomach’s low pH can quickly denature peptides, unfolding their complex 3D shapes and rendering them biologically inactive.

• Enzymatic “Digestion”: The GI tract is saturated with proteases and peptidases (enzymes) specifically evolved to break down peptides into individual amino acids for nutrition.

• The Permeability Barrier: Peptides are typically large, hydrophilic (water-loving), and charged. This prevents them from passively diffusing through the lipophilic (fat-loving) cell membranes of the intestinal wall.

• First-Pass Metabolism: Even if a peptide reaches the bloodstream via the gut, it often travels directly to the liver, where it can be rapidly cleared before reaching its target.

• Low Bioavailability: Due to these factors, oral peptides historically achieved less than 1% bioavailability (the amount actually reaching systemic circulation) compared to near $100 % for injections.

2. Technological Developments (The 2026 Landscape)

To overcome these hurdles, scientists have moved beyond simple “pills” to complex delivery vehicles and “robotic” devices.

A. Chemical Permeation Enhancers (The SNAC Breakthrough)

• SNAC (Salcaprozate Sodium): Used in oral semaglutide (Rybelsus), SNAC creates a localized “micro-environment” with a higher pH to protect the peptide from acid. It also fluidizes the cell membrane, allowing the peptide to slip through transcellularly. The newly offered oral Wegovy is basically higher dose Rybelsus. The oral bioavailability of Rybelsus (semaglutide) using SNAC (Salcaprozate Sodium) technology is approximately 0.4% to 1%.

• GIPET™ and TPE Technology: Technologies like Transient Permeation Enhancer (TPE) use medium-chain fatty acids (like sodium caprylate) to briefly open the “tight junctions” between cells, allowing peptides to pass through the gaps. Oral options for desmopressin, low molecular weight heparin, alendronate and oral insulin have used this technology.

B. Ingestible “Robotic” Pills (Mechanical Injection)

• SOMA (Self-Orienting Milliscale Applicator): Inspired by the shell of a leopard tortoise, this robotic pill always lands upright in the stomach. Once it hits the stomach lining, it triggers a spring-loaded “micro-needle” made of compressed drug (like insulin) to inject directly into the stomach wall.

• RaniPill™: An ingestible capsule that travels to the small intestine, where the higher pH inflates a tiny balloon. This balloon pushes dissolvable micro-needles into the intestinal wall—a pain-free process since the intestines lack sharp-pain receptors.

• These technologies are not presently being used but are being researched.

C. Advanced Nano-Formulations

• Lipid-Based Carriers (SEDDS): Self-Emulsifying Drug Delivery Systems encapsulate peptides in tiny oil droplets. These droplets mimic dietary fats, tricking the body into absorbing the peptide through the lymphatic system, effectively bypassing the liver. This technology is used now for two prescription products and is being researched for oral insulin and enoxaparin (low molecular weight heparin).

• Mucoadhesive Patches: Micro-scale patches designed to stick to the intestinal lining and release a high concentration of the peptide directly into the tissue, protecting it from being washed away by GI fluids.

D. Sublingual Thin-Films

• ODF (Oral Dissolvable Films): Newer platforms like BioNxt’s thin-film technology allow peptides to be absorbed under the tongue (sublingual). This bypasses the entire GI tract and the liver, providing a much faster and more direct route to the bloodstream.

• This technology is being studied for several different products including an oral delivery of cladribine, used for Multiple Sclerosis and Myasthenia Gravis.

• BioNxt is adding rights to a new chaperone technology for peptides and other complex molecules.

E. Oral Generic Equivalents For Rybelsus

Have recently been made available in India and potentially Canada. The core patents for the semaglutide compound expired on March 20, 2026, in several major markets, most notably India and China.

• In India: This week is considered “Day 1” for generic semaglutide. Leading Indian pharmaceutical firms like Sun Pharma, Zydus Lifesciences, and Torrent Pharmaceuticals are launching generic versions. Torrent is specifically focused on the oral tablet equivalent of Rybelsus.

• In the U.S.: There is no FDA-approved generic for Rybelsus. Due to a complex web of secondary patents (covering the SNAC delivery technology and specific weight-loss uses), U.S. generic entry is not expected until 2031 or 2032.

• Canada: Regulatory experts predict generic semaglutide could appear in Canada as early as late 2026, significantly ahead of the U.S. market.

Let’s Wrap This Up

The Future of Peptides: Access vs. Analysis

The recent “de-escalation” of the war on peptides by Secretary Kennedy marks a pivotal moment where patient demand has effectively forced a regulatory hand. As we move into this new era of “Category 1” compounding and the potential for “robotic” oral delivery, the barrier to access is crumbling. However, as a physician, my primary concern remains the gap between plausibility and proof. While the “Wolverine Stack” and other protocols offer a tantalizing glimpse into a future of rapid recovery and metabolic optimization, they are currently being deployed without the long-term safety data or standardized monitoring we require for traditional medicine. We are essentially watching a massive, real-world clinical trial unfold in real-time. If you choose to explore these pathways, I urge you to move away from the “grey market” and toward the emerging legal, compounded channels where medical oversight can at least ensure that your quest for the Fountain of Youth doesn’t come at the cost of your long-term metabolic health.

Share

Leave a comment

I think it appropriate for the public to try grasping how much research is published for the medical community.

According to Google AI, for U.S. physicians, the following are currently considered the most reputable and widely referenced “big” journals:

• New England Journal of Medicine (NEJM): Established in 1812, it remains the most prestigious peer-reviewed medical journal, particularly for clinical trials and original research.

• Journal of the American Medical Association (JAMA): A staple for U.S. practitioners, providing broad editorial coverage and highly cited peer-reviewed articles across all medical disciplines.

• The Lancet: While based in the UK, it is globally influential and a primary reference for international health and significant specialty research.

• The BMJ (British Medical Journal): Known for its rigorous standards and focus on medical education and clinical practice.

• Annals of Internal Medicine: The official journal of the American College of Physicians, highly regarded for its focus on Internal Medicine and healthcare policy.

• Nature Medicine: Often cited for translational research and breakthroughs that bridge the gap between basic science and clinical application.

I will say that the Journal of American Medical Association has become the rag for international healthcare policy with an occasional real scientific article. They worked hard at sabotaging COVID treatment studies during the Pandemic (aka Plandemic). In my view, JAMA is a government mouth piece touting medically irrelevant “wishes” of international health care policy. The journal totally misses the fact that health care populations are local and regional and it is a Prometheus effort to force universal standards to our country.

Likewise, the NEJM provides an excessive academic representation in their opinion articles. This journal does still offer more rigorous research articles and excellent reviews of medical diseases.

The Lancet and British Journal of Medicine (BJM)- British publications- need I say more??

Annals of Internal Medicine. Historically a great journal and in my opinion, the most reliable journal for real scientific inquiry. It is born from the American College of Physicians. Granted, they too, have fallen prey to certain political biases but they are still scientifically the more rigorous of the present modern day medical journals.

Nature Medicine??? Not a physician read journal. It is, however a good source for bench research. Bench research is hypothesis generating BUT not necessarily clinically relevant.

A Journal Missing….

The American Journal Of Medicine. This “Top 3 U.S Medical journals” was placed into the ash heap of the internet search options when Dr. Peter McCullough offered to clinicians the COVID Outpatient Treatment Protocol. I have always considered this medical journal worthy of my precious reading time.

So What Is Doctor Kordonowy Reading?

My readers know I have reported on the myth vs science of coffee and caffeine. Here again is a recent article addressing a common question. “Should I stop drinking coffee now that I have a diagnosis of Atrial Fibrillation ( a form of rapid and irregular heart beats).

Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation The DECAF Randomized Clinical Trial

The DECAF Randomized Clinical Trial (November 2025) disputes the myth that coffee causes heart arrhythmias, finding that daily consumption may actually reduce atrial fibrillation recurrence by 39%. Furthermore, studies indicate that moderate coffee intake is associated with lower risks of heart failure and stroke, while encouraging physical activity. Read the full story at UCSF News.

Why Coffee Might Be Good for Your Heart Rhythm

For years, many doctors and patients believed that caffeine was a “trigger” for heart rhythm issues like Atrial Fibrillation. However, recent clinical evidence suggests the opposite may be true for many people.

1. The “Conventional Wisdom” vs. Reality

Traditionally, it was thought that caffeinated coffee was proarrhythmic (meaning it promotes irregular heart rhythms). The DECAF trial was specifically designed to test this theory by comparing patients who drank coffee to those who avoided it entirely.

2. Lower Risk of Recurrence

The study found that patients who had recently undergone treatment for persistent AF (cardioversion) actually fared better when they consumed coffee:

• Coffee Group: Only 47% had a recurrence of AF within six months.

• Abstinence Group: 64% had a recurrence of AF within the same timeframe.

• The Result: Drinking at least one cup of caffeinated coffee daily was associated with a 39% lower hazard of the arrhythmia returning.

3. Potential Protective Mechanisms

While the study focused on the results rather than the biological “why,” researchers and the AHA often point to several ways coffee may protect the heart:

• Antioxidant Properties: Coffee is a major source of antioxidants, which can reduce inflammation and “remodeling” of the heart tissue.

• Adenosine Blocking: Caffeine blocks adenosine receptors; since adenosine can sometimes shorten the heart’s electrical recovery period (potentially triggering AF), caffeine may provide a stabilizing effect.

• Improved Heart Health: Regular consumption has been linked to lower risks of other heart-related issues, which indirectly keeps the heart’s electrical system healthier.

Statin Medication and Coronary Events

Diabetes is a well established associated condition with acute myocardial infarction (heart attack). Recent articles are confirming a mild increased incidence of the medical definition of diabetes with the use of statin medications prescribed for cholesterol lowering in at risk patients.

A recent study confirmed that the benefits of statin prescription in diabetic patients clearly outweighed any risk of medication use. In fact, ALL CAUSE mortality was benefited in the Statin group.

This is an important and might I say and ADDITIVE study supporting cholesterol lowering in high risk patients for coronary and other macrovascular events.

Statin initiation was associated with reductions in all-cause mortality and major CVD across QRISK3 strata. In the low-risk stratum, RDs and RRs were −0.53% (95% CI, −0.90% to −0.08%) and 0.80 (95% CI, 0.67 to 0.97), respectively, for all-cause mortality and −0.83% (95% CI, −1.28% to −0.34%) and 0.78 (95% CI, 0.66 to 0.91), respectively, for major CVD. A small increased risk for myopathy was observed in the moderate-risk stratum only, and there was no associated increased risk for liver dysfunction in any stratum.

Note- the myth that statins promote liver disease and medically relevant harm is again refuted in this study. I am really tired of patients reporting their “literature” social feeds “notices” that using proven lipid lowering medication is harmful.

Genetic Association with Disease. Hypothesis Generating But Not Ready For Prime Time

A recent study looking at analyzing common genetic variants associated with coronary artery disease confirms that the lion’s share of at risk coronary artery events is “POLYGENIC” versus single gene associated. This review is interesting to me because it demonstrates how the heart disease problem early on was assessed through familial inheritance patterns.

The lipid/cholesterol GEEKs were the first major discipline that, starting with Mendelian inheritance pedigree analysis, linked specific single gene defects (related to cholesterol metabolism) with early deaths from heart attacks.

That research led to the now proven hypothesis that elevated LDL cholesterol resulted in early death from coronary occlusion of cholesterol burdened plaques and associated thrombosis. Heterozygous and homozygous hypercholesterolemia are the two primary pedigrees of this association.

Doctors can find these patient subjects by measuring the phenotypical presentation- namely LDL cholesterol levels in the 95th percentile or higher. If these values are further linked with family histories of early heart attacks, the diagnostic certainty rises to very high levels.

Yet… this group represents a small proportion of heart attack victims. Enter the polygenic inquiry. It turns out there are currently tens of genetic variants, some of which are associated with cholesterol metabolism and thus measured levels, but many that are associated with other metabolic pathways a separation or more distant from cholesterol metabolism

So far studies confirm that in most cases it is a multitude of genetic variants that additively contribute to early heart attack risk. Unfortunately as of now, the concept of incorporating across the board genetics analysis to risk predict high risk patients has very low yield. I suspect that with time and especially with quantitative computing the precision of genetic analysis will eventually become clinically useful. Even though there are multiple genetic associations that are not directly linked to LDL cholesterol, LDL lowering lowers events in polygenetic high risk patients.

THE MAIN POINT I OBTAIN FROM THIS RESEARCH IS THAT A FAMILY HISTORY OF EARLY HEART ATTACK INDICATES A CLEAR GENETIC RISK FACTOR, SINGLE GENE OR POLYGENIC. THIS SHOULD CARRY MORE WEIGHT THAN OUR CURRENT “ RISK ASSOCIATION QUERIES” USED IN HISTORICAL RISK ASSESSMENTS TOOLS.

A Final Point

From genetic reported information when an individual has a polygenic risk (family history), it turns out behavior/lifestyle changes have an equal positive benefit for outcome as medical intervention. THIS MEANS, IN THE CONTEXT OF A POSITIVE FAMILY HISTORY OF EARLY HEART ATTACK, CURRENT MEDITERANIAN DIET AND ACTIVITY RECOMMENDATIONS WORK AS WELL AS MEDICATION INTERVENTION. LIKEWISE ALL MEDICATION TRIALS ASSESSING LDL CHOLESTEROL LOWERING SHOW CLINICAL BENEFIT FOR CARDIAC EVENTS AND ALL CAUSE MORTALITY. WHAT ISN’T KNOWN BASED UPON CURRENT LITERATURE IS WHETHER COMBINING LIFESTILE CHANGES WITH LDL LOWERING MEDICATIONS IS SUPERIOR TO EACH INDIVIDUAL APPROACH.

This is what we physicians are trying to prevent. Heart attack and (associated stroke) are still the main preventable afflictions in America.

Share

Leave a comment

For decades, Medicaid has operated as a vast and complex joint federal–state program with limited public visibility into how hundreds of billions of dollars are actually spent at the provider level. With nearly a trillion dollars in annual expenditures and millions of beneficiaries spanning vulnerable populations — including children, disabled individuals, and the elderly — oversight has historically relied on fragmented audits, state reporting, and retrospective enforcement actions. The release of a detailed national payment dataset changes that dynamic in a fundamental way. Transparency alters behavior. When patterns become visible, anomalies become detectable, and incentives shift. Whether intentionally framed this way or not, the signal being sent to the system is unmistakable: federal oversight is increasing, scrutiny is expanding beyond traditional enforcement channels, and participants across the Medicaid ecosystem — from providers to contractors to state programs — should recognize a new reality. In short, the message is simple: the cops are coming.

Background: Medicaid Crowdsourcing and Program Context

Medicaid Data Crowdsourcing Initiative

The U.S. Department of Health and Human Services publicly released a large national Medicaid provider payment dataset covering 2018–2024 in early February 2026 (Feb 7–9 window). The dataset includes provider-level spending by procedure code (HCPCS) and month, where HCPCS (Healthcare Common Procedure Coding System) refers to the standardized billing codes used across U.S. healthcare to identify medical services, procedures, equipment, and supplies for payment purposes. The stated purpose of the release is to enable public examination of waste, fraud, and abuse within Medicaid by allowing analysts to evaluate patterns of utilization and payments across providers and regions. This effort represents one of the first major attempts at open forensic auditing of a federal entitlement program using publicly accessible data.

No Confirmed Government Fraud Findings Yet From the New Dataset

As of today:

There have been no official federal announcements identifying specific providers or states as fraudulent based on the newly released crowdsourced dataset itself.

The release is still very recent (early February 2026), and formal investigations take months to years.

However — signals are emerging.

Public Claims From Analysts and Commentary

Several early analyses circulating online claim large anomalies:

• One analysis reportedly suggested tens of billions in “likely fraudulent payments” from a small subset of providers examined.

• These claims are not verified findings — they are interpretations of billing patterns.

Some national coverage highlights:

• Claims that the data could expose high-billing providers and questionable patterns, including autism services in certain states such as Minnesota.

• Public statements from political figures asserting the dataset may reveal “billions” in fraud.

These are assertions, not confirmed enforcement outcomes. The infrastructure for identifying fraud has been created, but validated findings have not yet emerged publicly. Early analyses of the newly released Medicaid payment data have identified unusual billing patterns in certain sectors and regions, but no formal government fraud determinations have yet been announced. It takes months to years for the legal process to be worked through.

Based on historical federal audits and improper payment studies, the most realistic estimate is that overall Medicaid fraud likely falls in the low single-digit to mid-single-digit range, with improper payments (which include documentation errors and eligibility issues, not just fraud) typically reported around 5–8% nationally. The probability that true fraud exceeds 10% across the entire Medicaid program is therefore relatively low — likely in the 10–20% range — because a substantial portion of spending flows through hospitals, managed care plans, and institutional providers that operate with greater regulatory oversight and compliance infrastructure. Large public datasets such as the recently released Medicaid payment files also tend to identify billing outliers before any determination of wrongdoing, meaning early signals should be interpreted as risk indicators rather than proof. In practical terms, past experience suggests some fraud will almost certainly be identified over time, but broad claims of systemic double-digit fraud across the entire program are not strongly supported by historical evidence.

Certain sectors, however, present a very different risk profile. Areas historically associated with fragmented oversight — including home and community-based services, behavioral health programs, durable medical equipment suppliers, and transportation services — have demonstrated significantly higher anomaly rates in enforcement actions, meaning localized fraud percentages in those niches could plausibly exceed 10–20% even while the overall program remains much lower. This concentration effect explains why large fraud headlines periodically emerge despite relatively modest aggregate fraud estimates: wrongdoing tends to cluster in smaller, labor-intensive service segments rather than in hospital or traditional physician billing. As a result, early analyses of the newly released data are most likely to surface outliers in these higher-risk sectors first, with validation requiring deeper clinical and documentation review.

Fellow Health Care cost analyst and SubStack writer, Dutch Rojas was one of the first social media contributors to point out the higher-risk sector of personal care billing in New York that warrants a closer Federal look. How in the world do we monitor or verify family caregivers working for mom or pop in their daily home health services? Did everyone know these Medicaid programs/billing codes exist?

Why is Medicaid In The News?

High Points: Medicaid Spending and Eligibility After ACA Expansion. The Medicaid Budget Nearly Equals Medicare’s Annual Costs Now!

Medicaid is a joint federal–state health insurance program that now spends approximately $850–900 billion annually, nearly double its size prior to the Affordable Care Act (ACA), when spending was roughly $450 billion. The program serves about 80 million Americans, making it the largest public insurance program in the United States. Although Medicaid is often discussed as a program for low-income populations broadly, its spending is highly concentrated in specific eligibility groups, particularly individuals who qualify due to disability and elderly beneficiaries who require long-term care services.

Eligibility for Medicaid falls into three major categories: income-based adults (including ACA expansion populations), disabled individuals, and elderly beneficiaries, many of whom are also enrolled in Medicare. The ACA expansion, implemented in 2014, primarily added working-age adults with incomes up to 138% of the federal poverty level, increasing enrollment by roughly 20–23 million people nationwide. These expansion beneficiaries tend to be younger and healthier, with annual costs averaging roughly $6,000–9,000 per person, which is substantially lower than costs for disabled or elderly enrollees.

Despite representing only about 20–25% of Medicaid enrollees, individuals who qualify due to disability and elderly beneficiaries account for approximately 50–60% of total Medicaid spending. This actually makes sense. Working-age disabled beneficiaries often incur annual costs between $15,000–25,000, while elderly beneficiaries — especially those requiring nursing home or long-term services — may exceed $20,000–40,000 per year. A large portion of this spending occurs among the dual-eligible population (people enrolled in both Medicare and Medicaid), which numbers about 12–13 million Americans and accounts for roughly 30% of Medicaid expenditures despite representing a minority of enrollees.

The ACA expansion significantly changed Medicaid demographics but did not fundamentally alter the core cost drivers of the program. Most of the increase in enrollment came from able-bodied adults qualifying through income rather than disability, which lowered the proportion of disabled and elderly beneficiaries within the program but did not reduce their absolute numbers or spending impact. Expansion spending today is estimated at roughly $150–200 billion annually, meaning that only part of Medicaid’s overall growth since 2014 is attributable directly to expansion; other drivers include medical inflation, long-term care costs, managed care payments, and demographic aging.

The key structural reality is that Medicaid now functions as two programs simultaneously: a large income-based insurance program for low-income adults and children, and a high-cost medical and long-term care safety net for disabled and elderly populations. Even after ACA expansion, the majority of Medicaid dollars continue to flow toward medically complex beneficiaries rather than the newly insured income-eligible adults.

Is Medicare Next?

The release of national Medicaid payment data has also triggered a much more consequential question: is Medicare next? From a structural standpoint, the answer increasingly looks like yes. Medicare represents an even larger pool of federal spending than Medicaid, operates under centralized federal authority, and already collects standardized claims data across hospitals, physicians, and outpatient services, making technical transparency easier to implement. At the same time, scrutiny of Medicare has intensified — particularly around Medicare Advantage (Part C) plans, where private insurers such as UnitedHealth and other large carriers receive risk-adjusted payments from the federal government that have been repeatedly criticized by watchdog agencies for potential overbilling, upcoding incentives, and opaque financial flows. Billions of dollars in payment disputes, audit findings, and litigation involving Medicare Advantage organizations have elevated political pressure for greater accountability.

When combined with the policy rationale already used to justify the Medicaid dataset — transparency, fraud detection, and taxpayer oversight — the logic becomes difficult to ignore. While no formal announcement has been made, the trajectory is clear: once the federal government demonstrates that large entitlement payment systems can be opened to public scrutiny, pressure naturally shifts toward the larger program. In that context, the Medicaid release may not be an endpoint, but rather a proof of concept. For stakeholders across healthcare — particularly insurers, contractors, and providers participating in federal programs — the implicit message is hard to miss: the era of limited visibility into public healthcare spending may be ending, and Medicare could very well be next.

As Medicare Insolvency Accelerates Forward

I expect that Uncle Sam will push the public to help find fraudulent dollars. It became crystal clear to me many years back that this come-to-Jesus event was inevitable. As primary care doctors were getting frog-boiled in the hot kettle, the “easiest” adjustment to keep themselves financially whole and in practice was to create the Hybrid care model. Quitting Medicare was perceived as just too shocking. But now as this fraud issue unfolds, I see cause for real concern.

Medicare Concierge / MDVIP-Style Hybrid Version

The possibility of expanded Medicare payment transparency carries particular relevance for physicians participating in Medicare while also charging patients membership or concierge fees — including models similar to MDVIP and other hybrid practices. Medicare does not reimburse physicians for “access” itself, but it does pay for the professional evaluation and management services that occur once access is obtained. When a membership fee is required for patients to obtain physician availability, communication, or coordination that may reasonably overlap with covered services, regulators could interpret the arrangement as a form of supplemental payment tied to Medicare-covered care, creating potential exposure under beneficiary inducement or double payment theories. Many concierge programs attempt to mitigate this risk by defining memberships as covering amenities or non-covered services, but the practical boundary between amenities and access to covered care can become blurred, particularly if membership participation is effectively required to remain in the practice.

None of this implies that concierge or hybrid models are inherently improper; many operate within legal guidance. However, increased federal visibility into physician billing patterns could make hybrid arrangements easier to identify and evaluate, especially if payment models appear to create financial barriers to accessing Medicare-covered services.

By contrast, physicians operating fully outside third-party reimbursement — such as in true direct primary care structures — avoid this layered payment issue entirely. This means leaving Medicare which is essentially an admission that the program isn’t serving doctors nor patients. A single payment relationship with the patient removes ambiguity about who is paying for what service and reduces regulatory exposure associated with overlapping compensation streams. As policy momentum moves toward greater scrutiny of federal healthcare spending, physicians should recognize that practice models combining public reimbursement with private membership revenue may attract more attention than those built on transparent, direct patient payment alone. To me, this is cause for concern and it could happen far faster than many think.

Professionally, the safest place in modern healthcare isn’t inside the payment system — it’s outside of it, where the transaction is voluntary, transparent, and conflict-free. Those in government trying to address the payment morass understand this but the powers that be are formidable. The public “call to action” indicates things are and must continue changing.

Share

Leave a comment

TrumpRx is a prescription drug pricing initiative launched by the U.S. federal government in 2026. It’s centered around a government-operated website at trumprx.gov that displays discounted prices on selected prescription medications and connects consumers to ways of buying them at those prices.

It is not an e-retail pharmacy. It is basically a website that functions as a market facilitator. It is posting the products that the manufacturers have agreed to offer “most favored nation” prices to the cash pay only customers in America. The site states this is the initial offering list with an intention to add more.

But upon analyzing the offers I can tell you this program is more hype than beef. This reminds me of a blog I wrote where I mentioned then, President Biden’s, “pharma sweetheart deal” for drug discounts for Medicare beneficiaries.

Excerpt:

Well…. TrumpRx is No Different!

Clearly the president didn’t have the right people in the room when he “got down and dirty” with big pharma. Nearly all of the pills being “offered” on Trump Rx can be purchased in the generic form at a further fraction of the cost of the “big discount” on name brands. This means if people are gullible enough to use the program for the pills, Big Pharma gets to take a lost share from the generic market. This leads to patients paying a premium for a brand name, even when a cheaper, equally effective equivalent exists.

After analyzing the offerings in more detail, we can see three medication categories within this government formulary. The most significant from a cost savings perspective is the biological grouping. I will save the latter part of this post to dive into that in more detail. This part of the pharmaceutical market is the most difficult to understand AND appears to have the most market distortion and usury in the present insurance payment model. After we walk through this project, I will summarize where I think there is actual benefit for consumers. It will be a pretty short list, I do say.

The largest and second category is the pill grouping. I chose to include the pill Wegovy in the third category as it is a specialized delivery of a technically “pill” form as it is rapidly dissolving. Within the pill grouping there are three products that are presently name brand only. They are Duavee, Farxiga, and Xeljanz.

The third category includes a hodgepodge of products with relatively small market penetration with arguably the lung inhalation medications being an exception. Following is a illustration of the categories/list.

Understanding the Manufacturer Landscape

Pfizer currently represents the single largest manufacturer contributor to the TrumpRx medication list. While the program is presented broadly as a drug pricing initiative, the product mix shows a meaningful concentration from one company across multiple therapeutic areas, including hormone therapy, immunology, dermatology, and urology. This concentration does not invalidate the program, but it does provide important context when interpreting the scope of participation and the degree of market representation.

Pfizer-manufactured products on the TrumpRx list include:

• Abrilada® (adalimumab biosimilar)
• Duavee®
• Eucrisa®
• Premarin®
• Premarin® Vaginal Cream
• Prempro®
• Toviaz®
• Xeljanz®

This amounts to roughly one in five medications on the list coming from a single manufacturer.

To place that in perspective, the U.S. pharmaceutical market is vastly larger than the subset represented in this program. The FDA supply chain includes thousands of manufacturing facilities worldwide, and hundreds of companies hold approved drug applications for products marketed in the United States. Even when narrowing to recognizable commercial players with meaningful market share, there are dozens of major pharmaceutical manufacturers operating across branded and generic markets.

In practical terms:

• Hundreds of companies have FDA-approved drugs available in the U.S. market
• Dozens of major manufacturers compete across therapeutic categories
• Thousands of global manufacturing facilities supply the U.S. drug ecosystem

Against that backdrop, the TrumpRx list reflects participation from only a small fraction of the available pharmaceutical marketplace. Noting the large scale of the overall potential market, the present core manufacturers participating in Trump Rx are:

Pfizer
Novo Nordisk
Eli Lilly
AstraZeneca
Merck
Organon
Various smaller specialty manufacturers

How TrumpRx Works for Patients (Or Does It Work At All)?

TrumpRx is a cash-price medication program. It is designed primarily for people who are paying for prescriptions out of pocket rather than using insurance.

In practical terms, the website does two main things:

• It links patients to discount coupons (similar to GoodRx) that can be used at participating retail pharmacies.
• It connects patients to manufacturer pricing programs for certain medications, especially higher-cost specialty drugs and biologics.

The site itself does not manufacture medications, and it is not an insurance plan. It functions more like a pricing navigation tool. From my deep dive into this story, I would suggest it is more like a social services program than a marketplace.

When someone goes shopping, one of two things will happen. They will be linked to the GoodRx network OR they will be diverted to a specialized manufacturer fulfillment program. The manufacturer fulfillment program will basically result in a long form questionnaire that will be looking for any loophole to get them out of helping you. You will be asked upon your honor that you don’t have insurance. This is because they want to keep you trapped into a much more lucrative insurance prescription scheme. I will explain that a bit later in this post. You will next be asked to provide proof of income needs or ability. This process is couched in the phrase “meet eligibility requirements”.

For some higher-cost medications — especially biologics — patients may be routed to manufacturer programs.

These programs sometimes include:

• Income thresholds
• Insurance status questions
• Prior authorization confirmation
• Specialty pharmacy enrollment
• Physician paperwork
• Consent forms

This is because manufacturers already operate:

Patient Assistance Programs (PAPs) or affordability programs.

TrumpRx may be directing patients into those existing systems.

And Then There Is GoodRx

GoodRx is not insurance and it is not a pharmacy network owner. GoodRx is a price-aggregation and coupon platform that connects three parties:

• Pharmacy Benefit Managers (PBMs)
• Pharmacies
• Patients paying cash

The key point:

GoodRx uses existing PBM discount networks that pharmacies already participate in.

GoodRx didn’t individually contract with every pharmacy in America. They plugged into networks that already existed. As a side note, that is how Obamacare got people into insurance. The plans simply leased existing insurance contracts onto the ACA insurance card.

Biologics: Why They Are Different From Traditional Drugs

As I started this project, I was very excited to find patients a deal. Biologic medications are notoriously expensive and have their own sanctioned patent process. On TrumpRx, the first drug offering in the alphabetical drug listing menu is the biologic medication Abrilada^{® .}

This is Pfizer’s version of a biosimilar biologic immune injection medication. It turns out Humira® from the pharmaceutical manufacturer AbbVie was the original inventor of the molecule and held patent protection until 2023. Now there are ten manufacturers making a version of this following the patent expiration.

Biologic medications are produced using living systems rather than chemical synthesis. They are typically large, complex proteins — such as monoclonal antibodies, hormones, or engineered peptides — whose final structure depends not only on the genetic sequence but also on the manufacturing process itself.

Because of this complexity, biologics cannot be copied in the same way that traditional small-molecule drugs can.

The Core Regulatory Distinction

Traditional drugs follow a generic pathway.
Biologics follow a biosimilar pathway.

Small-Molecule Drugs

• Chemically synthesized
• Structurally simple and fully characterizable
• Generic versions are chemically identical
• Approval based primarily on pharmacokinetic equivalence

Biologics

• Produced in living cells
• Large, structurally complex proteins
• Manufacturing process affects final product
• Exact duplication is impossible

Therefore: Biologics have “biosimilars,” not true generics.

Biologic drugs are fundamentally different from traditional medications. They are complex proteins produced in living systems, and their structure depends on the manufacturing process itself. As a result, follow-on versions are biosimilars — highly similar but not identical — rather than true generics. Multiple patent layers and regulatory exclusivity periods further limit competition, which is why biologic markets tend to evolve more slowly and maintain higher prices than conventional drugs.

Among the biologic medications listed on the TrumpRx platform, only a minority currently have biosimilar competition. Most of the highest-profile drugs, including semaglutide and tirzepatide products, remain under active patent protection with no approved biosimilar alternatives. As a result, price reductions in these categories reflect manufacturer pricing decisions rather than true competitive market forces.

While getting affordable generic pill alternatives to the market happens routinely, this isn’t the case for biosimilar products due to the unique methods of production and getting regulatory approval for these compounds.

Fact:

International markets offer somewhat greater biosimilar competition for older biologic classes, but the newest high-cost drugs — particularly GLP-1 and dual-agonist therapies — remain under patent protection worldwide. Geography does not overcome patent barriers, which means pricing power for these products remains largely manufacturer-controlled across global markets.

This last illustration shows the public what a giant rip off our present health insurance funded prescription fulfillment process is. Recall, GoodRx harnesses itself into this scheme.

My Conclusion:

If you are on an expensive biologic medication and are prepared to provide personal and financial information to the manufacturer, this site may be helpful. You likely can access these same programs by going to the manufacturer existing websites. If you are on the few name brand products in the other categories, you will have a decent chance of getting a GoodRx coupon and access better prices. A large majority of the non biologic prescriptions already have very affordable generic alternatives that your local pharmacy, our dispensary (for our patients), Amazon Rx or Mark Cuban’s e-retail pharmacy can fill for you.

Share Dr. Kordonowy's Newsletter

“No fear of the unnamed
Stand up like a man taking the whole blame
Someone's got to do it
Someone's got to”

Steve Earle’s “Unrepentant”

What Follow is My Anthem and Another Call To Action/“How To” For My Fellow Doctors-Specialists Included

In the first two essays of this series, we looked at what Medicare’s “virtual hospital” experiment quietly revealed. Patients with conditions traditionally labeled “inpatient” — pneumonia, heart failure, COPD exacerbations, infections often coded as sepsis — were treated safely at home with off site monitoring, nursing support, and daily physician oversight. Outcomes were similar to conventional hospital care. Transfers back were uncommon. Lengths of stay were comparable.

Once you see those results, a simple conclusion follows: the hospital building itself is not the therapeutic ingredient. But there is a deeper implication that is even more important for practicing physicians. The real story is not about billing classifications or institutional privilege. It is about physics and technology. The constraints that once forced acute care inside hospital walls are steadily dissolving.

Continuous pulse oximetry, Bluetooth blood pressure cuffs, connected scales, wearable cardiac monitors, rapid mobile diagnostics, and high-resolution telehealth are no longer just possible. These tools are being sold directly to consumers, dispelling the barrier and past conditioning that only hospitals and highly specialized locations offered such services.

In that sense, the “virtual hospital” project did not invent anything new. It simply acknowledged a reality that had already arrived: modern monitoring has dispersed. The hospital no longer has a monopoly on information density.

Medicine has quietly become portable and is becoming more personalized and individually consumed. Our anchored payment process and lack of imagination is holding us back from returning to the doctor’s house call.

Dr.’s Marconi, Barry and I already provide encompassing care and services from within our office. In special situations we have been known to call on patients in their home if time and circumstances allow. With our full time scheduling and clinical staff, we provide IV fluids and or medication infusions to provide acute and effective therapy, avoiding hospitalization and emergency room referrals.

My observations are making it clear to me that artificial intelligence application is leading to large language modeling around a patient’s health record, personal diaries and health monitoring information to help in persons measuring choices on health metrics. Expanded rules clarifying that tech companies can’t and don’t hold patient data hostage inside a “tech silo” or institutional structure (hospital system), means central control of your health record and information is not in our future.

Logic takes me to the conclusion that collaborating with our patients, will result in even more effective benefit for patients. It also is intuitive that if we incorporate the present infrastructure of the extensive United States logistics in place, it isn’t a stretch at all to extend our impact and treatment range to our patients homes.

Emphasis- A nuance worth noticing: who adopted first

Interestingly, early participation in Medicare’s hospital-at-home waiver skewed heavily toward large, urban, teaching hospital systems. Rural and smaller hospitals were far less likely to implement programs. That pattern appears to reflect organizational capacity rather than clinical feasibility. Large systems had staffing depth and administrative infrastructure to launch quickly. Smaller hospitals did not.

Yet rural communities may benefit the most. In many regions, patients travel hours for care or face shrinking hospital access altogether. Home-based acute care could be not merely convenient, but essential.

The technology works anywhere. Adoption simply followed resources first.

This observation reframes the story again. Hospital-at-home is less a hospital innovation and more a proof of concept that acute care is no longer tied to geography.

Which leads naturally to an uncomfortable but productive question for physicians:

If hospitals were able to move acute care into the home, what actually prevents us from doing the same?

The regulatory question most physicians get wrong

There is a common assumption that hospital-level care must legally occur inside a hospital. That belief turns out to be more cultural than statutory.

When we step outside Medicare’s inpatient billing framework and simply read the law, the environment is surprisingly permissive.

Medicare rules say only hospitals may bill inpatient DRGs (Diagnostic Related Group Billing). But that governs billing classification — not the practice of medicine. DRG payment is a government/Medicare payment scheme thrust upon the system in the Nixon era. It has embedded itself into the conditioned payment method for hospitalization services (in hospitals).

To verify that Nixon’s administration created the DRG Medicare payment scheme, consider the following points:

1. The Diagnosis-Related Group (DRG) system was introduced in 1983.

2. It was part of the Medicare program reforms initiated under the Nixon administration.

3. The goal was to control rising healthcare costs and improve efficiency.

4. The DRG system categorizes hospital cases into groups for payment purposes.

5. It shifted Medicare from cost-based reimbursement to a fixed payment system.

6. The implementation was influenced by the Health Insurance Portability and Accountability Act (HIPAA) in 1996.

Outside that billing structure, what applies is simply state medical practice law. In Florida, as in most states, physicians may diagnose and treat wherever the patient happens to be. Home visits are legal. Telehealth is legal. IV therapy under physician order is routine. Nurses may operate under physician supervision.

Nothing in statute says acute care must occur inside a hospital.

The only real restrictions appear if a practice accidentally becomes something else:

• a licensed hospital with beds

• a standalone home health agency

• or an insurance product pooling risk

Avoid those classifications and physicians are simply practicing medicine. In other words, the walls that constrained acute care were financial and historical, not legal or clinical. That distinction matters. Because once you recognize that nothing actually prohibits physicians from managing acute illness at home, the conversation shifts from “Are we allowed?” to “How would we build it?”

Reclaiming the physician’s role

For decades, primary care gradually ceded acute illness to hospitals. The pattern became automatic: deterioration → emergency department → admission → handoff to hospitalists. The Hospitalist movement which took hold in the early 2000’s decimated the traditional doctor patient relationship and contract. This was a ruse thrust upon us by academia. Corporate hospitals loved this “story” and as doctors had been brow beaten into overworked mules, we bought the story as well. We needed SOME time off, afterall. Getting out of hospital patient rounding was a strong incentive to go along with this scheme. I am here to state clearly, this model DID NOT IMPROVE patient care, safety nor outcomes (somebody’s got to do it).

But if monitoring, nursing, diagnostics, and physician oversight can now be coordinated around the patient rather than inside an institution, the hospital handoff is no longer inevitable. In many cases, the patient’s own physician is best positioned to manage the episode. They know the history, medications, and baseline. Technology simply extends their reach. Hospital-at-home, viewed this way, is not primarily a hospital story. It is a physician opportunity.

How to Build AcuteCare@Home in a Primary Care Practice

Things look bad from over here
Too much confusion and no solution
Everyone here knows your fear
You're out of touch and you try too much

Lyrics From Steppenwolf’s “Move Over”

Once you accept that much of routine inpatient medicine is portable, the operational design becomes surprisingly straightforward. This is not about recreating a hospital in miniature. It is about extending ordinary internal medicine into the home using tools already available.

Think of it less as “hospital-at-home” and more as enhanced physician-directed home management.

Step 1 — Define the clinical envelope

Focus on diagnoses that require monitoring and medication rather than procedures. If you have a patient who you know is trending towards hospitalization, consider offering this added service option. The virtual hospital system confirmed the following items and I added wound care and management. Hypertensive urgency could be another scenario. Recent but completed, non-interventional stroke is a situation where intense “observational” monitoring at home would be appropriate.

• pneumonia needing IV antibiotics

• cellulitis (skin infection)

• Pulmonary disease or asthma exacerbations

• heart failure diuresis therapy and monitoring

• complicated UTIs (urinary tract infections)

• stable infection syndromes

• Wound care and management

Exclude hypotension, altered mentation, escalating oxygen needs, or anything requiring ICU (Intensive Care Unit) resources. In other words, use the same stability filter hospitals already apply.

Step 2 — Build the monitoring layer

Deploy simple connected tools: Artificial Intelligence and Data Gathering services especially with the new FYR platforms will allow office based intense patient monitoring and trend alert programs.

• pulse oximetry

• BP cuffs

• weight scales

• wearables

• telehealth check-ins

This often yields more continuous data than a traditional ward.

Step 3 — Add nursing execution

Partner with:

• employed or contracted nurses

• home health agencies

• mobile labs

• community paramedics

• Amazon, Uber or Lyft for urgent product delivery.

They become the physician’s extenders delivering IVs, drawing labs, medications, durable medical equipment and reporting findings.

Step 4 — Consider Specialist Consultation Collaboration

Arrange Virtual or Home physician consultation collaboration and patient care dashboard sharing. Neurology, radiology, pulmonary, etc are fields that come to mind.

Step 5 — Establish escalation pathways

Create clear protocols for rapid transfer when instability appears. The hospital becomes the backup, not the default. Forward thinking hospitals will create a collaborative urgent admission process. Presently the Emergency Room remains everyone’s crisis option.

Step 6 — Explore The Cost and Price of Delivering This Level Of Care

Use:

• direct care agreements- we love direct to consumer pricing, leave the mischief of third party intermediaries back in the insurance business.

• per diem billing

• Hourly supervision charges/fees

• bundled episode or disease diagnosing pricing

• employer contracts

• hybrid/DPC models

Payment aligns with the episode rather than the building.

Step 6 — Start small

Pilot with a few diagnoses and patients. Refine workflow. Expand gradually. I think this is something all physicians COULD consider, especially if government policies and rules get reviewed, revised and reinvented.

At its core, AcuteCare@Home (you read it here first) is not a new specialty. It is primary care reclaiming territory it once managed routinely, now supported by modern technology.

Hospital-at-home demonstrated that acute medicine no longer depends on walls.

The next logical step is recognizing that it may not need hospital ownership either.

If the tools are portable and the outcomes are comparable, then the responsibility — and the opportunity — naturally return to physicians. Build it and they will come.

ONE CAN DREAM